Demise of Merck's weekly DPP-4 may reflect tough diabetes market

Januvia box

Once upon a time, Merck was looking to candidate omarigliptin—a once-weekly DPP-4 diabetes med—to build up declining sales of its Januvia/Janumet franchise.

But no more. Late last week, the pharma giant quietly announced that it had dropped the Phase III prospect it once regarded as a key cog in its diabetes plans.

So why the change of heart? A new report from healthcare analytics firm Advera Health Analytics found that the weekly therapy came along with more serious side effects than Januvia in two studies. Omarigliptin turned up higher rates of prostate cancer and cardiovascular and hepatobiliary issues, or problems with the liver, pancreas or digestive system, it found. And that kind of profile could have made the drug a hard sell.

Infographic

[Infographic] Machine Learning, Statistics and Optimizing Outcomes

In our infographic, we outline the potential of fusing machine learning and statistics algorithms together to more efficiently analyze clinical trial data output and ultimately revolutionize clinical research.

Merck says the decision didn’t result from any safety or efficacy concerns. Instead, it may have taken a look at the diabetes landscape and seen a difficult future for the DPP-4 contender.

Such a conclusion would come as no surprise, considering recent developments in the diabetes world. Last year, SGLT2 med Jardiance from Eli Lilly and Boehringer Ingelheim made headlines when it became the first diabetes med to cut down on the combined risk of heart attack, stroke and cardiovascular-related death. Last month, GLP-1 product Victoza from Novo Nordisk accomplished the same feat. And those outcomes leave DPP-4s—which have shown that they don’t increase the risk of serious cardiovascular events, but don’t reduce it, either—out in the cold.

And omarigliptin’s once-weekly advantage may not have done enough to change that, considering the long-acting GLP-1 options out there. Eli Lilly is already marketing once-weekly Trulicity, and Novo is in Phase III with its own long-lasting GLP-1, semaglutide.

But that’s not to say Merck will be left in the dust. With omarigliptin off its hands, the company plans to double down on its pipeline efforts, which include ertugliflozin--an SGLT2 prospect of its own.

- read Merck's release 

Special Report: The top 10 best-selling diabetes drugs of 2013

Related Articles:
Merck's DPP-4 newcomer Marizev trails Januvia in safety: Report
Victoza comes up big for Novo with key heart-risk lowering data
Jardiance and its CV data? They're no knockout punch for stalwart Januvia, Merck says
You say you want a revolution? Lilly, BI and Jardiance may trigger one in diabetes

Suggested Articles

Think you’re busy? Take a look at Pfizer’s commercial team for oncology, which is currently juggling eight launches. And that’s just in the U.S.

Bristol-Myers Squibb is out to expand the pool of colorectal cancer patients it can treat with Opdivo—and it’s bringing in Bayer to help.

Contradicting analysts' observations, Novartis CEO dubbed Zolgensma “one of the most successful launches from an access standpoint in rare diseases.”